Indirect comparisons of competing interventions

Health Technology Assessment

Volumn 9, Issue 26, 2005, Pages

  Glenny, A M ^a   Altman, D G ^b   Song, F ^c   Sakarovitch, C ^b   Deeks, J J ^b   D'Amico, R ^b   Bradburn, M ^b   Eastwood, A J ^d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^d UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AURANOFIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAFFEINE; CODEINE; CORTICOSTEROID; COTRIMOXAZOLE; CYANOCOBALAMIN; DEXTROPROPOXYPHENE PLUS PARACETAMOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DROPERIDOL; ERYTHROMYCIN; FLUOROURACIL; FOLIC ACID; GOLD; HEPARIN; INTERFERON; LEVAMISOLE; MALOPRIM; MESALAZINE; METHOTREXATE; METOCLOPRAMIDE; PARACETAMOL; PENICILLAMINE; PLACEBO; PYRIDOXINE; ROXITHROMYCIN; SALAZOSULFAPYRIDINE; UNINDEXED DRUG;

ABSTRACT REPORT; ACCURACY; CLINICAL PROTOCOL; CLINICAL STUDY; CLINICAL TRIAL; COLORECTAL CANCER; COMPARATIVE STUDY; COMPUTER PROGRAM; CONGESTIVE HEART FAILURE; DATA ANALYSIS; DATA BASE; DECISION MAKING; DRUG TOLERABILITY; EMPIRICAL RESEARCH; EXPERIMENTAL DESIGN; HEART INFARCTION; HEPATITIS C; HUMAN; HYPERHOMOCYSTEINEMIA; INFORMATION PROCESSING; INTERMETHOD COMPARISON; LOWER RESPIRATORY TRACT INFECTION; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; METHODOLOGY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PAIN; PNEUMOCYSTIS PNEUMONIA; PUBLISHING; RANDOMIZATION; REGRESSION ANALYSIS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SIMULATION; STATISTICAL ANALYSIS; STATISTICAL MODEL; STROKE; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; VARIANCE; VOMITING;

EID: 21244495516     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta9260     Document Type: Review

References (152)

1. Pocock SJ. Clinical trials: a practical approach. New York: John Wiley; 1996.
2. Moher D, Schulz KF, Altman D. CONSORT Group (Consolidated Standards of Reporting Trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285:1987-91.
3. Song F, Glenny AM. Antimicrobial prophylaxis in colorectal surgery: a systematic review of randomised controlled trials. Health Technol Assess 1998;2(7).
4. de Craen AJM, Tijssen JGP, de Gans J, Kleijnen J. Placebo effect in the acute treatment of migraine: subcutaneous placebos are better than oral placebos. J Neurol 2000;247:183-8.
5. McAlister FA, Laupacis A, Wells GA, Sackett DL. Users' Guides to the Medical Literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect. JAMA 1999;282:1371-7.
6. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum 1990;33:1449-61.
7. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273:1450-6.
8. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ 1998;316:894-8.
9. Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996;348:771-5.
10. Moore A, McQuay H, Gray M, editors. Bandolier. Oxford: Pain Relief Unit. URL: http://www.jr2.ox.ac.uk/bandolier/
11. Tramer MR, Moore RA, McQuay HJ. Prevention of vomiting after paediatric strabismus surgery: a systematic review using the numbers-needed-to-treat method. Br J Anaesth 1995; 75:556-61.
12. de Craen AJM, Vickers AJ, Tijssen JGP, Fleijnen J. Number-needed-to treat and placebo-controlled trials. Lancet 1998;351:310.
13. Murray DW, Britton A, Bulstrode CJ. Thromboprophylaxis and death after total hip replacement. J Bone Joint Surg Am 1996; 78-B:863-70.
14. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91.
15. Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, et al. Evaluating non-randomised intervention studies. Health Technol Assess 2003;7(27).
16. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. II. Maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ 1994; 308:159-68.
17. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
18. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. III. Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 1994; 308:235-46.
19. Lowenthal A, Buyse M. Secondary prevention of stroke: does dipyridamole add to aspirin? Acta Neurol Belg 1994; 94:24-34.
20. Li Wan Po A, Zhang WY. Systematic overview of co-proxamol to assess analgesic effects of addition of dextropropoxyphene to paracetamol. BMJ 1997;315:1565-71.
21. Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut 1997;40:775-81.
22. Matchar DB, McCrory DC, Barnett HJ, Feussner MD. Medical treatment for stroke prevention. Ann Intern Med 1994; 121:41-53.
23. Milne RJ, Olney RW, Gamble GD, Turnidge J. Tolerability of roxithromycin vs erythromycin in comparative clinical trials in patients with lower respiratory tract infections. Clinical Drug Investigation 1997;14:405-17.
24. Moore A, Collins S, Carroll D, McQuay H. Paracetamol with and without codeine in acute pain: a quantitative systematic review. Pain 1997;70:193-201.
25. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993; 153:477-84.
26. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996;24:778-89.
27. Zhang WY, Li Wan Po A. Analgesic efficacy of paracetamol and its combination with codeine and caffeine in surgical pain - a meta-analysis. J Clin Pharm Ther 1996;21:261-82.
28. Piccinelli M, Pini S, Bellantuono C, Wilkinson G. Efficacy of drug treatment in obsessive-compulsive disorder: a meta-analytic review. Br J Psychiatry 1995;166:424-43.
29. Zalcberg JR, Siderov J, Simes J. The role of 5-fluorouracil dose in the adjuvant therapy of colorectal cancer. Ann Oncol 1996;7:42-6.
30. Leizorovicz A. Comparison of the efficacy and safety of low molecular weight heparins and unfractionated heparin in the initial treatment of deep venous thrombosis. An updated meta-analysis. Drugs 1996;7:30-7.
31. Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992;327:1618-24.
32. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer; a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311:899-909.
33. Rossouw JE. Lipid-lowering interventions in angiographic trials. Am J Cardiol 1995;76:86-92C.
34. Koch M, Dezi A, Ferrario F, Capurso L. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. Arch Intern Med 1996;156:2321-32.
35. Holme I. Cholesterol reduction and its impact on coronary artery disease and total mortality. Am J Cardiol 1995; 76:10-17C.
36. Moore RA, McQuay HJ. Single-patient data meta-analysis of 3453 postoperative patients: oral tramadol versus placebo, codeine and combination analgesics. Pain 1997;69:287-94.
37. Aro J. Cardiovascular and all-cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population. Prostate 1991;18:131-7.
38. Poynard T, Lemaire M, Agostini H. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol 1995;7:661-5.
39. Lefering R, Neugebauer EAM. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med 1995; 23:1294-303.
40. Chiba N, de-Gara CJ, Wilkinson FM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112:1798-810.
41. Coulter A, Kelland J, Peto V, Rees MC. Treating menorrhagia in primary care: an overview of drug trials and a survey of prescribing practice. Int J Technol Assess Health Care 1995;11:456-71.
42. Bansal VK, Beto JA. Treatment of lupus nephritis: a meta-analysis of clinical trials. Am J Kidney Dis 1997; 29:193-9.
43. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996;275:1507-13.
44. Unge P, Berstad A. Pooled analysis of anti-Helicobacter pylori treatment regimens. Scand J Gastroenterol Suppl 1996; 220:27-40.
45. Imperiale TF, Speroff TS. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. JAMA 1994; 271:1780-5.
46. Conlin PR, Spence JD, Williams B, Ribeiro AB, Saito I, Benedict C, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000; 13:418-26.
47. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-22.
48. Ekbom A, Taube A. Methodological flaws in study on prostatic cancer. Prostate 1994;25:53-4.
49. NHS Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness. CRD guidelines for those carrying out or commissioning reviews. Report No. 4. York: NHS Centre for Reviews and Dissemination; 1996.
50. Berkey CS, Anderson JJ, Hoaglin DC. Multiple-outcome meta-analysis of clinical trials. Stat Med 1996;15:537-57.
51. Dominici F, Parmigiani G, Wolpert RL, Hasselblad V. Meta-analysis of migraine headache treatments: combining information from heterogeneous designs. Journal of the American Statistical Association 1999;94:16-28.
52. Hasselblad V. Meta-analysis of multitreatment studies. Med Decis Making 1998;18:37-43.
53. Higgins JP, Whitehead A. Borrowing strength from external trials in a meta-analysis. Stat Med 1996;15:2733-49.
54. Hirotsu C, Yamada Y. Estimating odds ratios through the connected comparative experiments. Communications in Statistics - Theory and Methods 1999;28:905-29.
55. Gleser LJ, Olkin I. Meta-analysis for 2 × 2 tables with multiple treatment groups. In Stangl DK, Berry DA, editors. Meta-analysis in medicine and health policy. New York: Marcel Dekker; 2001. pp. 179-89.
56. Gleser LJ, Olkin I. Stochastically dependent effect sizes. In Cooper H, Hedges LV, editors. The handbook of research synthesis. New York: Russell Sage; 1994. pp. 340-55.
57. Deeks JJ. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Stat Med 2002;21:1575-600.
58. Davey Smith G, Egger M. Going beyond the grand mean: subgroup analysis in meta-analysis of randomised trials. In Egger M, Davey Smith G, Altman DG, editors. Systematic reviews in healthcare. Meta-analysis in context. 2nd ed. London: BMJ Books; 2001. pp. 143-56.
59. Thompson SG. Why and how sources of heterogeneity should be investigated. In Egger M, Davey Smith G, Altman DG, editors. Systematic reviews in healthcare. Meta-analysis in context. 2nd ed. London: BMJ Books; 2001. pp. 157-75.
60. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In Egger M, Davey Smith G, Altman DG, editors. Systematic reviews in health care: Meta-analysis in context. London: BMJ Books; 2001. pp. 285-312.
61. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003; 326:219.
62. Thompson SG, Higgins JPT. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002;21:1559-73.
63. Anderson S, Hauck WW. The transitivity of bioequivalence testing: potential for drift. Int J Clin Pharmacol Ther 1996; 34:369-74.
64. Hauck WW, Anderson S. Some issues in the design and analysis of equivalence trials. Drug Information Journal 1999; 33:109-18.
65. Mainland D. The treatment of clinical and laboratory data. Edinburgh: Oliver and Boyd; 1938. pp. 151-3.
66. Armitage P, Berry G. The sampling error of a difference. In Statistical methods in medical research. 2nd ed. Oxford: Blackwell; 1987. pp. 88-90.
67. Eddy DM, Hasselblad V, Schachter R. Meta-analysis by the confidence profile method. Boston, MA: Academic Press; 1992.
68. Hasselblad V, Kong DF. Statistical methods for comparison to placebo in active-control trials. Drug Information Journal 2001; 35:435-49.
69. Packer M, Antonopoulos GV, Berlin JA, Chittams J, Konstam MA, Udelson JE. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am Heart J 2001;141:899-907.
70. Fisher LD, Gent M, Butler HR. Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo. Am Heart J 2001; 141:26-32.
71. Baker SG, Kramer BS. The transitive fallacy for randomized trials: if A bests B and B bests C in separate trials, is A better than C? BMC Med Res Methodol 2002;2:13.
72. Clarke MJ, Stewart LA. Obtaining data from randomised controlled trials: how much do we need for reliable and informative meta-analysis? BMJ 1994;309:1007-10.
73. Higgins JP, Whitehead A, Turner RM, Omar RZ, Thompson SG. Meta-analysis of continuous outcome data from individual patients. Stat Med 2001;20:2219-41.
74. Smith CT, Williamson PR, Marson AG. Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes Stat Med 2005;24:1307-19.
75. Brown H, Prescott R. Applied mixed models in medicine. Chichester: John Wiley; 1999.
76. Ades AE. A chain of evidence with mixed comparisons: models for multi-parameter synthesis and consistency of evidence. Stat Med 2003;22:2995-3016.
77. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Methods for meta-analysis in medical research. Chichester: John Wiley; 2000.
78. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 1999; 18:2693-708.
79. Lim E, Ali A, Routledge T, Edmonds L, Altman DG, Large S. Indirect comparison meta-analysis of aspirin therapy after coronary surgery. BMJ 2003; 327:1309-11.
80. Lim E. First principles or evidence based critique? URL: http://bmj.bmjjournals.com/cgi/eletters/327/7427/1309#46233 (accessed September 2004).
81. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian approaches to clinical trials and health-care evaluation. Chichester: John Wiley; 2004.
82. Phillips A. Trial and error: cross-trial comparisons of antiretroviral regimens. AIDS 2003;17:619-23.
83. Senn S. Active control equivalence trials. Statistical issues in drug development. Chichester: John Wiley; 2002. pp. 207-17.
84. Siegel JP. Equivalence and non-inferiority trials. Am Heart J 2000;139:S166-70.
85. ICH Harmonised Tripartite Guideline. Choice of control group and related issues in clinical trials. URL: http://www.nihs.go.jp/dig/ich/efficacy/e10/e10step4.pdf (accessed March 2005).
86. Engels EA, Schmid CH, Terrin N, Olkin I, Lau J. Heterogeneity and statistical significance in meta-analysis: an empirical study of 125 meta-analyses. Stat Med 2000;19:1707-28.
87. Song F, Glenny AM, Altman DG. Indirect comparison in evaluating relative efficacy - illustrated by antimicrobial prophylaxis in colorectal surgery. Control Clin Trials 2000;21:488-97.
88. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med 2002;21:2313-24.
89. Chan A-W, Altman DG. Epidemiology and reporting of randomised trials published in PubMed journals. Lancet 2005; 365:1159-62.
90. Lambert PC, Sutton AJ, Jones DR. A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis. J Clin Epidemiol 2002;55:86-94.
91. Berlin JA, Santanna J, Schmid CH, Szczech LA, Feldman HI. Individual patient- versus group-level data meta-regression for the investigation of treatment effect modifiers: ecological bias rears its ugly head. Stat Med 2002;21:371-87.
92. Turner RM, Omar RZ, Yang M, Goldstein H, Thompson SG. A multilevel model framework for meta-analysis of clinical trials with binary outcomes. Stat Med 2000;19:3417-32.
93. Begg CB, Pilote L. A model for incorporating historical controls into a meta-analysis. Biometrics 1991;47:899-906.
94. Li Z, Begg CB. Random effects models for combining results from controlled and uncontrolled studies in a meta-analysis. Journal of the American Statistical Association 1994;89:1523-7.
95. Raghunathan TE. Pooling controls from different studies. Stat Med 1991;10:1417-26.
96. Büchner T, Dohner H, Ehninger G, Ganser A, Hasford J. Up-front randomization and common standard arm: a proposal for comparing AML treatment strategies between different studies. Leuk Res 2002;26:1073-5.
97. Büchner T, Dohner H, Ehninger G, Ganser A, Niederwieser D, Hasford J. Cross-trial networking in AML: a step forward rather than corner cutting. Leuk Res 2004;28:649-50.
98. Hills RK, Richards SM, Wheatley K. Corner cutting compromises clinical trials: the inherent problems with up-front randomisation and a common standard arm. Leuk Res 2003;27:1071-3.
99. Tsong Y, Wang SJ, Hung HM, Cui L. Statistical issues on objective, design, and analysis of noninferiority active-controlled clinical trial. J Biopharm Stat 2003;13:29-41.
100. Wang SJ, Hung HM, Tsong Y. Utility and pitfalls of some statistical methods in active controlled clinical trials. Control Clin Trials 2002;23:15-28.
101. Sandercock PAG, Collins R, Counsell C, Farrell B, Peto R, Slattery J, et al. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke. Lancet 1997; 349:1569-81.
102. Sterne JAC, Bradburn MJ, Egger M. Meta-analysis in Stata™. In Egger M, Davey Smith G, Altman DG, editors. Systematic reviews in health care. Meta-analysis in context. London: BMJ Books; 2001. pp. 347-85.
103. Bradburn MJ, Deeks JJ, Altman DG. Metan-an alternative meta-analysis command (sbe24) [correction appears in Stata Technical Bulletin, No. 45, 21 (sbe24.1)]. Stata Technical Bulletin 1998; 44:4-15.
104. Sharp S. sbe23: Meta-analysis regression. Stata Technical Bulletin 1998;42:16-24.
105. Robinson LD, Jewell NP. Some surprising results about covariate adjustment in logistic-regression models. International Statistical Review 1991; 59:227-40.
106. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003;326:472-5.
107. Rostom A, Wells G, Tugwell P, Welch V, Dube C, McGowan J. Prevention of chronic NSAID induced upper gastrointestinal toxicity. In The Cochrane Library (Issue 3). Oxford: Update Software; 2000.
108. Soo S, Moayyedi P, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia. In The Cochrane Library (Issue 3). Oxford: Update Software; 2000.
109. 2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. In The Cochrane Library (Issue 3). Oxford: Update Software; 2000.
110. Palmer BV, Mannur KR, Ross WB. An observer blind trial of co-amoxiclav versus cefuroxime plus metronidazole in the prevention of postoperative wound infection after general surgery. J Hosp Infect 1994;26:287-92.
111. Rowe-Jones DC, Peel ALG, Kingston RD, Shaw JFL, Teasdale C, Cole DS. Single dose cefotaxime plus metronidazole versus three dose cefuroxime plus metronidazole as prophylaxis against wound infection in colorectal surgery: multicentre prospective randomised study. BMJ 1990; 300:18-22.
112. Kwok SPY, Lau WY, Leung KL, Ku KW, Ho WS, Li AKC. Amoxycillin and clavulanic acid versus cefotaxime and metronidazole as antibiotic prophylaxis in elective colorectal resectional surgery. Chemotherapy 1993;39:135-9.
113. Altman DG, Deeks JJ. Meta-analysis, Simpson's paradox, and the number needed to treat. BMC Med Res Methodol 2002;23.
114. Altman DG, Dore CJ. Randomisation and baseline comparisons in clinical trials. Lancet 1990; 335:149-53.
115. Schulz KE, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273:408-12.
116. Song F, Eastwood A, Gilbody S, Duley L, Sutton A. Publication and related biases. Health Technol Assess 2000;4(10).
117. Chan A-W, Hròbjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004; 291:2457-65.
118. Villar J, Carroli G, Belizan JM. Predictive ability of meta-analyses of randomised controlled. Lancet 1995; 345:772-6.
119. Cappelleri JC, Ioannidis JPA, Schmid CH, Ferranti SD de, Aubert M, Chalmers TC, et al. Large trials vs meta-analysis of smaller trials. How do their results compare? JAMA 1996; 276:1332-8.
120. LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 1997;337:536-42.
121. Abel U, Koch A. The role of randomization in clinical studies: myths and beliefs. J Clin Epidemiol 1999; 52:487-97.
122. Jüni P, Altman DG, Egger M. Assessing the quality of randomised controlled trials. In Egger M, Davey Smith G, Altman DG, editors. Systematic reviews in health care. Meta-analysis in context. London: BMJ Books; 2001. pp. 87-108.
123. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ 1996;312:1215-18.
124. McQuay HJ, Moore RA. An evidence-based resource for pain relief. Oxford: Oxford University Press; 1998.
125. Bandolier. The Oxford league table of analgesic efficacy. URL: http://www.jr2.ox.ac.uk/bandolier/booth/painpag/acutrev/analgesics/ lftab.html (accessed September 2004).
126. European Collaboration on Craniofacial Anomalies (Eurocran). URL: http:/www.eurocran.org/content.asp?contentID=1345 (accessed September 2004).
127. Sackett DL. Rules of evidence and clinical recommendations on the use of asymptomatic atherosclerosis. Stroke 1989; 20:844-9.
128. Poynard T. Evaluation de la qualite methodolgique des essais therapeutiques randomises. Presse Med 1988;17:315-88.
129. Marshall JK, Irvine EJ. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther 1995;9:293-300.
130. Chalmers TC, Smith H Jr, Blackburn B, Silverman B, Schroeder B, Reitman D et al. A method for assessing the quality of a randomized control trial. Control Clin Trials 1981;2:31-49.
131. Liberati A, Himel HN, Chalmers TC. A quality assessment of randomized control trials of primary treatment of breast cancer. J Clin Oncol 1986; 4:942-51.
132. Evans M, Pollock AV. A score system for evaluating random control clinical trials of prophylaxis of abdominal surgical wound infection. Br J Surg 1985;72:265-70.
133. Jadad AR, Moore RA, Carrol D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomised clinical trials: is blinding necessary? Control Clin Trials 1996; 17:1-12.
134. Poynard T, Pignon JP. Duodenal ulcer. Analysis of 293 randomized clinical trials. London: Montrouge, John Libbey Eurotext; 1989.
135. DerSimonian R, Charette LJ, McPeek B, Mosteller F. Reporting on methods in clinical trials. N Engl J Med 1982; 306:1332-7.
136. Schmieder RE, Schlaich MP, Klingbeil AU, Martus P. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant 1998;13:564-9.
137. Cheng L, Gulmezoglu AM, Ezcurra E, van-Look PFA. Interventions for emergency contraception (Cochrane Review). In The Cochrane Library (Issue 3). Oxford: Update Software; 2000.
138. Collins SL, Moore RA, McQuay HJ, Wiffen PJ, Edwards JE. Single dose oral ibuprofen and diclofenac for postoperative pain (Cochrane Review). In The Cochrane Library (Issue 3). Oxford: Update Software; 2000.
139. Delaney BC, Innes MA, Deeks JJ, Wilson S, Oakes R, Moayyedi P et al. Initial management strategies for dyspepsia (Cochrane Review). In The Cochrane Library (Issue 3). Oxford: Update Software; 2001
140. Di Mario F, Battaglia G, Leandro G, Grasso G, Vianello F, Vigneri S. Short-term treatment of gastric ulcer. A meta-analytical evaluation of blind trials. Dig Dis Sci 1996;41:1108-31.
141. Handoll HHG, Farrar MJ, McBirnie J, Tytherleigh-Strong G, Awal KA, Milne AA, et al. Heparin, low molecular weight heparin and physical methods for preventing deep vein thrombosis and pulmonary embolism following surgery for hip fractures (Cochrane Review). In The Cochrane Library (Issue 4). Oxford: Update Software; 2002.
142. Horn J, Limburg M. Calcium antagonists for acute ischemic stroke (Cochrane Review). In The Cochrane Library (Issue 3). Oxford: Update Software; 2001.
143. McIntosh HM, Olliaro P. Artemisinin derivatives for treating uncomplicated malaria (Cochrane Review). In The Cochrane Library (Issue 3). Oxford: Update Software; 2001.
144. Silagy C. Physician advice for smoking cessation (Cochrane Review). In The Cochrane Library (Issue 3). Oxford: Update Software; 2001.
145. Silagy C, Mant D, Fowler G, Lancaster T. Nicotine replacement therapy for smoking cessation (Cochrane Review). In The Cochrane Library (Issue 3). Oxford: Update Software; 2001.
146. Trindade E, Menon D. Selective serotonin reuptake inhibitors (SSRIs) for major depression. Part I. Evaluation of the clinical literature. Report No. 3E. Ottawa, Ontario: Canadian Coordinating Office for Health Technology Assessment; 1997 August 1997.
147. Zhang WY, Li Wan Po A. Efficacy of minor analgesics in primary dysmenorrhoea: a systematic review. Br J Obstet Gynaecol 1998;105:780-9.
148. Ausejo M, Saenz A, Pham B, Kellner JD, Johnson DW, Moher D, et al. Glucocorticoids for croup (Cochrane Review). In The Cochrane Library (Issue 3). Oxford: Update Software; 2001.
149. Sauriol L, Laporta M, Edwardes MD, Deslandes M, Ricard N, Suissa S. Meta-analysis comparing newer antipsychotic drugs for the treatment of schizophrenia: evaluating the indirect approach. Clin Ther 2001;23:942-56.
150. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492-501.
151. Singer DE. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation. Ann Intern Med 2000; 132:841-2.
152. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-62.